Becker's Healthcare September 3, 2024
Swiss pharmaceutical company Sandoz is launching a generic semaglutide, the main ingredient of Ozempic, in the U.S. when the market opens in 2030, Bloomberg reported Sept. 3.
The company first plans to launch the generic, which is approved for Type 2 diabetes (Ozempic) and weight loss (Wegovy), in...